Phase III Trial of High-dose Melphalan and Stem Cell Transplantation Versus High-dose Melphalan and Bortezomib and Stem Cell Transplantation in Patients With AL Amyloidosis
Phase of Trial: Phase III
Latest Information Update: 01 Dec 2017
At a glance
- Drugs Bortezomib (Primary) ; Melphalan
- Indications Amyloid light-chain amyloidosis
- Focus Therapeutic Use
- Acronyms VelRand
- 03 Jul 2017 Status changed from suspended to discontinued for toxicity evaluation.
- 06 Jun 2016 Status changed from recruiting to suspended for toxicity evaluation.
- 07 Jul 2015 New trial record